Board of Trustees

We are governed by a Board of Trustees composed of 14 members, half of whom are lay members and half medical.

All Trustees are also members of Our Advisory Council - an advisory body comprising of up to 30 members.

Dr Doug Gurr

Chair of the Board of Trustees

Dr Doug Gurr became President of Amazon China in 2014 after joining Amazon UK in 2011. He has been a Trustee of the Landmark Trust since 2014, and is a non-executive Director at the Department of Work and Pensions. Dr Gurr was a Trustee of the Science Museum from 2004-2014 and was Chairman between 2010 and 2014.

From 2006 to 2011 he was Executive Development Director at Asda and a main Board Director of Asda Group Limited. He spent five years as Chief Executive at Blueheath - the internet-enabled stockless wholesaler he founded in 2001. He was a partner at McKinsey and Company from 1995 to 2001, and head of the UK retail practice. He read Mathematics at the University of Cambridge and has a PhD in Theoretical Computer Science from the University of Edinburgh.

Doug joined the Board of Trustees as Chair in October 2015. He is also Chair of the Nominations Committee, and a member of the Remuneration Committee.

Andrew Balfour LLB

Andrew Balfour is a retired solicitor who now spends his time working for a number of charities and educational institutions.

He retired from the international law firm Slaughter and May in 2011 after a career of over thirty years working for the firm. During that career he worked on a range of commercial transactions, but was primarily a financing lawyer advising on major borrowing transactions for many leading corporate and bank clients in the UK and elsewhere.

Andrew became a partner of Slaughter and May in 1988, worked in the firm’s New York office for a couple of years in the early 1990s and became head of the financing practice and a member of the partnership board in 2004. Since 2014 Andrew has been Chairman of the firm’s Africa Practice Group, a part time role that requires him to travel extensively in Africa.

In addition to his role for the BHF, Andrew is a trustee of Sustrans (the sustainable transport charity which continues to develop the National Cycle Network) and of Farleigh Hospice in Essex and is also a school governor.

In his spare time Andrew and his wife, Anne, enjoy being outside in the fresh air in Essex, where they live. They have supported the BHF for many years, following in the footsteps of Anne’s mother who was a leading fundraiser for the BHF in Winchester in the 1970s and 1980s. Andrew also enjoys watching sport, going to the theatre and cinema, gardening and walking and cycling in the countryside.

Andrew joined the Board of Trustees in 2012, and is a member of the Audit & Risk Committee.

Professor Dame Anna F Dominiczak DBE MD FRCP FRSE FMedSci

Professor Anna Dominiczak (OBE, MD, FRCP, FRSE, FMedSci) is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences at the University of Glasgow as well as honorary consultant physician and non-executive member of the NHS Greater Glasgow and Clyde Health Board.

One of the world’s leading cardiovascular scientists and clinical academics, Prof Dominiczak’s major research interests are in hypertension, cardiovascular genomics and precision medicine where she has not only published extensively in top peer-reviewed journals (total of 370 publications), but also excelled in large scale research funding for programmes and infrastructure alike (total value £70 million in the last 4 years). She has led a collaboration of four universities and four academic NHS Health Boards across Scotland to develop public/private partnership in Precision Medicine with a current value of £20 million. 

Prof Dominiczak is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh, the American Heart Association and the European Society of Cardiology.

She has published over 370 peer reviewed papers in top journals and is an immediate past President of the European Society of Hypertension and Editor-in-Chief of Hypertension, the journal of American Heart Association. In 2005 she was awarded OBE for services to medicine.  

Dr Robert Easton BSc ARCS DPhil

Chair of the Fundraising Board

Dr Robert Easton is a Partner and Senior Advisor to The Carlyle Group, the major global alternative asset manager. He was previously head of the firm’s private equity fund in Ireland, Co-Head of Carlyle Europe Technology Partners, a fund targeting Europe-wide growth capital and buyout transactions in the media, software, telecom and healthcare sectors, and prior to that he ran the firm’s UK buyout activities. He is based in London and has been with Carlyle for 16 years.

Prior to joining Carlyle, Dr Easton was Vice President of Corporate Development at Invensys plc. He was a key figure in the mid-nineties transformation of BTR from a diversified conglomerate to a focused engineering group and, following the merger of BTR and Siebe to form Invensys in 1999, in the further focusing of Invensys to become a leading Automation and Controls group.

Dr Easton joined BTR in 1996 from Trafalgar House, another major UK engineering group where he was Director of Corporate Finance and Planning. Prior to this he spent eight years in the investment banking business working initially for CSFB and then for Wasserstein Perella.

Dr Easton has a first class honours degree in chemistry from Imperial College in London and a Doctorate in organic synthesis from Oxford University.

In addition to his Directorships of Carlyle portfolio companies and numerous private company start-ups, Dr Easton is a past Chairman of the British Venture Capital Association, the trade association for private equity in the UK, and he currently sits on two boards at Imperial College, the Advisory Board of the Business School and the private sector Syndicate over-seeing the development if a new University campus at Imperial West. Dr Easton is also a Non-Executive Director of Imperial Innovations, the public company venture capital spin-out entity of Imperial College. 

Robert became a Trustee in 2013, he is also Chair of the BHF Fundraising Board, and a member of the Remuneration and Investment Committees.

Dr Evan Harris BM BCh MA (Oxon)

Evan Harris studied physiological sciences at Wadham College, Oxford and qualified in medicine in 1991. After training in general medicine with the Nuffield Department of Medicine at the Oxford Radcliffe Hospital, he worked in public health medicine.

He was MP for Oxford West and Abingdon from 1997 until 2010, a member of the Science and Technology Select Committee and Liberal Democrat Science spokesman from 2003.

He is currently an Honorary Senior Research Fellow at Queen Mary, University of London, and writes on science and medicine for the Guardian and the British Medical Journal.

Evan joined the Board of Trustees in 2011.

Richard Hytner MA LLM

Richard, a law graduate from St John’s College, Cambridge University. Until he established, in 2016, beta baboon, a creative management consultancy helping leadership teams to outperform their ambitions, Richard was Saatchi & Saatchi’s Worldwide Deputy Chairman. He joined Saatchi & Saatchi in 2003 as Chairman and CEO for Europe, Middle East and Africa, having graduated with distinction as a Sloan Fellow from London Business School where he is now Adjunct Associate Professor of Marketing, teaching MBA and Executive Education participants on topics that include Leading strategic transformation; strategic branding; communications; and creativity.

Richard is a trustee of Planting Promise, a sustainable educational enterprise in Sierra Leone; co- founder of the Manchester United Supporters’ Trust; and a non executive adviser to the Management Board of the Metropolitan Police.

Richard published Consiglieri: Leading from the Shadows, a celebration of those who make leadership contributions from beyond the CEO’s office. 

Richard joined the Board of Trustees in 2011 and is a member of the Nominations Committee.

Professor Sir Robert Lechler MB ChB PhD FRCP, FRCPE,  FRCPath, PMedSci

Robert Lechler qualified in Medicine in Manchester in 1975. Thereafter, he undertook four years of junior hospital doctor training in general medicine and nephrology before embarking on a PhD in transplantation immunology at the Royal Postgraduate Medical School.

Following the PhD, he returned to full-time clinical work for two years and completed his scientific training at the National Institutes of Health in Bethesda, USA. He returned to the UK to a Senior Lecturer Post at the Royal Postgraduate Medical School in 1986 and became Head of the Department of Immunology in 1994.

He became Dean of Hammersmith Campus at Imperial College Faculty of Medicine in 2001 and Head of the Division of Medicine in 2003. He moved to King’s College London as Head of the School of Medicine at Guy’s, King’s College and St Thomas’ Hospitals in September 2004 and was appointed Vice Principal (Health) at  King’s College in October 2005. In June 2009 he was appointed as Executive Director of King’s Health Partners Academic Health Sciences Centre. In 2012 he was awarded a knighthood for services to Academic Medicine and in December 2015 he was elected as the President of the Academy of Medical Sciences

Professor Lechler joined the Board of Trustees in 2010 and is also a member of the Nominations Committee.

Iain Mackay

Chair of the Audit & Risk Committee

Iain Mackay is Group Finance Director of HSBC Holdings Plc, a role he has held since December 2010. Iain joined HSBC in 2007 as CFO of HSBC North America Holdings Inc where he was instrumental in the restructuring of HSBC's consumer finance business. From 2009-2010 he was CFO Asia Pacific of HSBC Holdings Plc. Before joining HSBC, Iain was at General Electrics - initially as Controller of the Global Consumer Finance unit, then CFO of GE Healthcare - Global Diagnostic Imaging. From 1990-1996, Iain was a regional finance director with Schlumberger Dowell. Early in his career, Iain was with PriceWaterhouse in New York and Paris and Thomson McLintock, KMG in the UK.

Iain joined the Board of Trustees in 2015, and is Chair of the Audit & Risk Committee.

Professor Sussan Nourshargh PhD FMedSci FBPhS

Sussan Nourshargh is a pharmacologist who studied at University College London and King’s College London and became Professor of Immunopharmacology at Imperial College London in 2006. In 2007 she joined Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, to establish and head a new Centre focusing on Microvascular Research. Her research aims to unravel the molecular and cellular events involved in leukocyte trafficking and through the application of advanced in vivo imaging modalities her team have made seminal contributions to the fields of inflammation and vascular biology.

Professor Nourshargh is a Wellcome Trust Investigator and Fellow of the Academy of Medical Sciences and British Pharmacological Society. She has acted on numerous funding Boards including BHF Project Grant and Fellowship Committees and is currently member of the Wellcome Trust’s Biomedical Resources & Multi-User Equipment Grant Committee, Royal Society’s Newton Advanced Fellowship Panel, Academy of Medical Sciences SpringBoard Grant Scheme and she chairs the Academy of Medical Sciences Committee for selection of new Fellows in the fields of pharmacology, physiology and neurosciences. Sussan has also been on the panel of numerous national and international scientific advisory boards, has been recipient of several prestigious scientific awards and has held a number of editorial positions. 

Professor Nourshargh joined the Board of Trustees in 2015.

Professor Simon Ray

Simon Ray graduated in Pharmacology (1980) and Medicine (1983) from Bristol University. After early training in general medicine he completed an MD as a BHF funded research fellow with Professor Henry Dargie in Glasgow and then undertook specialist cardiology training in Newcastle, Liverpool and Vancouver. He was appointed consultant cardiologist at the University Hospitals of South Manchester in 1995 and Honorary Professor of Cardiology at the University of Manchester in 2011.

He has served as the President of the British Society of Echocardiography, Vice-President for Clinical Standards of the British Cardiovascular Society and is currently President of the British Heart Valve Society. He has wide ranging clinical interests within cardiology and his research interests are centred on heart valve disease.

Dr Ray joined the Board of Trustees in 2014.

Professor Liam Smeeth MBChB FRCGP FFPH FRCP MSc PhD

Liam Smeeth is professor of clinical epidemiology and Head of the Department of Non-communicable Disease Epidemiology at the London School of Hygiene and Tropical Medicine. He also undertakes clinical work as a general practitioner in north London.

Much of his research is based on making better use of computerised clinical data both to investigate drug effects and disease aetiology. He holds a Wellcome Trust Senior Fellowship in Clinical Science and is Deputy Director of the Farr Institute London, one of the four UK Health Informatics Research Centres. His work is largely in cardiovascular disease, with one area of particular interest being the causal role of infections and inflammation. Other areas of interest are genetic epidemiology and non-communicable diseases in low income settings. He is involved in a range of activities for NICE and the NHS more widely.

Liam joined the Board of Trustees in 2014.

Lance Trevellyan BSc(Hons) FCA FRSA

Lance Trevellyan is founder and Chairman of the Trevellyan Group, a trading and investment group specialising in petrol retailing, fine art publishing, property investment and development. Lance also established an international business based in Jersey specialising in art, property and investment in fund management.  He is a Fellow of the Institute of Chartered Accountants England and Wales, a Fellow of the Royal Society of Arts, Manufacture and Commerce and Trustee of Jersey Heritage. 

Lance joined the Board of Trustees in 2009 and is also a member of the Retail Committee.

Professor Sir Kent Woods MA MD SM FRCP FMedSci

Vice Chair of the Board of Trustees and Chair of the Advisory Council

Sir Kent Woods was the Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA) 2004-2013 and Chairman of the Management Board of the European Medicines Agency 2011-2015. He was previously Director of the NHS Health Technology Assessment Programme (1999-2003), commissioning research in and for the NHS.

A graduate of Cambridge and of Harvard School of Public Health, he was a consultant physician in cardiovascular medicine at Leicester Royal Infirmary from 1984-2003 and is Emeritus Professor of Therapeutics at Leicester University. He is a Fellow of the Academy of Medical Sciences and was knighted for services to healthcare in 2011.

Sir Kent joined the Board as Vice Chair in 2015. He is also Chair of the Advisory Council, and a member of the Nominations and Remunerations Committees.